RBC Adjusts Price Target on CorMedix to $14 From $13, Maintains Outperform Speculative Risk Rating
RBC Capital Markets has increased its price target for CorMedix (CRMD) to $14 from $13, while reiterating an Outperform Speculative Risk rating. This adjustment reflects a positive outlook on the company's financial prospects and potential market performance.